Saltar a Texto Principal

Investor Relations

Nitto always aims for fair disclosure to ensure that our investors can properly evaluate our corporate value.

Nitto always aims for fair disclosure to ensure that our investors can properly evaluate our corporate value.

What's New RSS

The Nitto website is currently under system maintenance. Please try again later.
2016/Nov/11 Bristol-Myers Squibb y Nitto Denko firman un acuerdo de licencia en exclusiva para todo el mundo para la terapia con ARNip orientado de esteatohepatitis no alcohólicas avanzadas (NASH, por sus siglas en inglés) y cirrosis debidas a la NASH
2016/Nov/02 Inicio de la Fase 1 de los ensayos clínicos de la vacuna contra la gripe estacional HA en comprimidos sublinguales
2016/Oct/31 Notice Regarding Dividends from Surplus and Revision of Dividend Forecast
Notice
 
Please be advised that except for current and past facts, the performance outlooks and business strategies presented in this Website are based on projections and judgments by NITTO DENKO management, and may differ from the actual performance.

Moreover, as it is not the intention of this Website to solicit any investments in NITTO DENKO stocks, visitors intending to do so are advised to make their investment decisions solely based on their own judgment.

Volver al Inicio de la Página